Mandate

New issue in AttgeNO

May 02, 2018 M&A

The Swedish pharmaceutical research company AttgeNO has performed a new issue of shares.

AttgeNO works on the development of new pharmaceuticals which expand blood vessels. Supernitro (PDNO) is a new, patented pharmaceutical candidate for treatment of acute and life-threatening high blood pressure in the lungs, which, can arise for example in connection with heart surgery and may result in death. The capital generated as a result of the new issue of shares is intended to give AttgeNO an opportunity to perform clinical Phase 1 studies during 2019.

AttgeNO was advised by partner Johan Winnerblad.

Related

Vinge advises Hallbyggarna Jonsereds in conjunction with the acquisition of Renthall

Hallbyggarna Jonsereds AB, part of the NSS Group, has acquired Renthall i Sverige AB, which has a turnover of SEK 40 million.
October 02, 2025

Vinge has advised in connection with the sale of Täby Air Maintenance AB and three Saab 2000 aircraft

Vinge has advised Erik Thun AB in connection with the sale of all shares in Täby Air Maintenance AB and three Saab 2000 aircraft to Wingefors Depå Sju AB.
October 02, 2025

Vinge advises Tengbom in connection with the acquisition of Suunnittelemo

Tengbom Finland is expanding and has established operations in Finland through the acquisition of Suunnittelemo Oy in Tammerfors.
October 01, 2025